🕒 Friday 30 January 2026 Fri, 30 Jan 2026

Golden Horse Minerals reports multiple shallow, high-grade gold intersections at Golden Valley and significant deep drilling success at Southern Cross, backed by a $35 million capital raise to fuel 2026 growth.

Holista Colltech has reported a positive operating cash flow for the December quarter, driven by disciplined cost management and a successful capital raise, despite softer sales and ongoing legal disputes.

Vita Resources NL, formerly Bastion Minerals, has advanced its Canadian and Australian projects with new exploration agreements and acquisitions, supported by a recent capital raise. The company is gearing up for significant exploration activities in 2026 under its refreshed corporate identity.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Cullen Resources Limited has outlined an active exploration agenda for early 2026, advancing drilling programs across its gold and base metal projects in Western Australia and Finland while maintaining a stable financial footing.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Manuka Resources has released an updated 10-year Pre-Feasibility Study for its Cobar Basin projects, revealing a substantial uplift in project economics and a clear path to production by mid-2026.

Power Minerals has commenced a significant 10,000m reverse circulation drilling program at its Santa Anna Project in Brazil, aiming to expand and deepen the footprint of high-grade niobium and rare earth elements mineralisation. Results are anticipated by late March 2026.

Emerald Resources NL reported solid December quarter gold production from its Okvau Gold Mine and significant resource upgrades at its Dingo Range and Memot projects, underpinning its growth trajectory.

Magmatic Resources has reported encouraging gold assay results from its Weebo Gold Project and advanced drilling at its Myall Copper-Gold JV, alongside securing a $3 million placement led by FMG Resources.

MRG Metals has expanded its rare earth portfolio through the acquisition of the high-grade Garies Rare Earth Project in South Africa, while also progressing key projects in Mozambique, signalling a diversified growth strategy in critical minerals.

Nagambie Resources and Alkane Resources have entered a binding agreement for a joint venture that could see Alkane invest up to $27.5 million to earn an 80% stake in Nagambie's key mining tenements, leveraging Alkane’s existing processing infrastructure to accelerate production.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Alpha HPA Limited has successfully raised A$225 million through a fully underwritten equity placement, bolstered by strong institutional support, to fund the next phase of its high purity alumina project. This capital injection, combined with existing cash and government funding, positions the company to advance its Stage 2 construction and expand Stage 1 capacity.

Evion Group gains momentum as the US-Africa Strategic Infrastructure and Investment Working Group fosters trade, Madagascar accelerates mining permits, and Indian graphite operations deliver strong sales.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Beetaloo Energy has secured key regulatory approvals and approved the Final Investment Decision for its Carpentaria Pilot Project, setting the stage for first gas sales from EP187 in late 2026.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

PainChek has secured FDA De Novo clearance, enabling entry into the vast US healthcare market with a $3 billion Remote Therapeutic Monitoring opportunity. The company reports $5.6 million contracted ARR and a strong global footprint in aged care.

Bougainville Copper Limited has selected China’s CMOC Group as its preferred partner to redevelop the Panguna Mine, but the Autonomous Bougainville Government’s president favors a rival Indian firm, casting uncertainty over the project’s future.

PentaNet Ltd reported a positive net operating cash flow of A$710,000 for the December 2025 quarter, alongside a strong cash position of A$2.42 million. The company completed its final payment for a 15-year 5G spectrum license while maintaining access to substantial financing facilities.

Pentanet has reported steady growth in Q2FY26, driven by a strong 5G revenue jump and sustained positive earnings before interest, tax, depreciation, and amortisation (EBITDA). The company’s new brand campaign and subscriber gains signal a strategic push into the second half of the fiscal year.

Range International Limited has reported its strongest quarterly sales and production figures yet in Indonesia, while strategically pivoting towards a pallet rental model to secure more stable revenue streams.

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.